Category Archives: 2022

PeproMene Bio, Inc. Announced Complete Response of The First Patient Treated in Its B-cell Non-Hodgkin Lymphoma (B-NHL) Phase 1 Clinical Trial of PMB-CT01 (BAFFR-CAR T Cells) at City of Hope

Posted on December 20, 2022 by steve@pepromenebio.com

Irvine, Calif., 20 Dec, 2022 — PeproMene Bio, Inc., a clinical-stage biotech company developing novel therapies to treat cancers and immune disorders, today announced that the first patient treated in its phase 1 relapsed or refractory B-cell Non-Hodgkin Lymphoma (r/r … Continue reading →

Posted in 2022 | Leave a comment